According to Qianyuan Pharmaceutical's announcement, the conditions for awarding the company's 2026 restricted stock incentive plan have been fulfilled. It was determined that September 4, 2026 will be the grant date. For the first time, 14 million Class 1 restricted shares will be awarded to 49 eligible incentive recipients at a price of 6.27 yuan/share. The source of the shares is the company's targeted issuance of A-share common shares. The total grant scale of this incentive plan does not exceed 17 million shares, including 3 million reserved shares. The initial partial sales restriction period was 12 months, 24 months, and 36 months from the date the grant registration was completed. The corresponding sales restrictions were 40%, 30%, and 30%, respectively. The assessment year was 2026-2028, and a dual performance assessment target was set for deducting non-net profit and smoking cessation drug sales revenue. The funds raised in this grant will be used to supplement working capital, and the total cost is estimated to be amortized at a total cost of RMB 34.02 million.

According to Qianyuan Pharmaceutical's announcement, the conditions for awarding the company's 2026 restricted stock incentive plan have been fulfilled. It was determined that September 4, 2026 will be the grant date. For the first time, 14 million Class 1 restricted shares will be awarded to 49 eligible incentive recipients at a price of 6.27 yuan/share. The source of the shares is the company's targeted issuance of A-share common shares. The total grant scale of this incentive plan does not exceed 17 million shares, including 3 million reserved shares. The initial partial sales restriction period was 12 months, 24 months, and 36 months from the date the grant registration was completed. The corresponding sales restrictions were 40%, 30%, and 30%, respectively. The assessment year was 2026-2028, and a dual performance assessment target was set for deducting non-net profit and smoking cessation drug sales revenue. The funds raised in this grant will be used to supplement working capital, and the total cost is estimated to be amortized at a total cost of RMB 34.02 million.